1196 related articles for article (PubMed ID: 34698889)
1. Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
Zhou Z; Curtis AJ; Ernst ME; Ryan J; Zoungas S; Wolfe R; McNeil JJ; Murray AM; Reid CM; Chowdhury EK; Woods RL; Tonkin AM; Nelson MR
Eur J Clin Pharmacol; 2022 Mar; 78(3):467-476. PubMed ID: 34698889
[TBL] [Abstract][Full Text] [Related]
2. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
3. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
Yebyo HG; Aschmann HE; Puhan MA
Ann Intern Med; 2019 Jan; 170(1):1-10. PubMed ID: 30508425
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG
J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394
[TBL] [Abstract][Full Text] [Related]
7. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
8. Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults.
Zhou Z; Ofori-Asenso R; Curtis AJ; Breslin M; Wolfe R; McNeil JJ; Murray AM; Ernst ME; Reid CM; Lockery JE; Woods RL; Tonkin AM; Nelson MR
J Am Coll Cardiol; 2020 Jul; 76(1):17-27. PubMed ID: 32616158
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
10. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
11. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Stein B; Ward T; Hale G; Lyver E
Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
[No Abstract] [Full Text] [Related]
12. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study.
Shin D; Yoon D; Lim SG; Hong JM; Park RW; Lee JS
PLoS One; 2016; 11(7):e0158130. PubMed ID: 27386858
[TBL] [Abstract][Full Text] [Related]
14. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
16. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
18. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.
Cai T; Abel L; Langford O; Monaghan G; Aronson JK; Stevens RJ; Lay-Flurrie S; Koshiaris C; McManus RJ; Hobbs FDR; Sheppard JP
BMJ; 2021 Jul; 374():n1537. PubMed ID: 34261627
[TBL] [Abstract][Full Text] [Related]
19. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease.
Foley TR; Singh GD; Kokkinidis DG; Choy HK; Pham T; Amsterdam EA; Rutledge JC; Waldo SW; Armstrong EJ; Laird JR
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28711864
[TBL] [Abstract][Full Text] [Related]
20. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]